Roche Holding AG
RHOA
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
112,774
Stocks News & Analysis
stocks
Investors punish this ASX player after acquisition
We think the floundering stock price is not reflective of underlying asset value.
stocks
Revenue growth on track for undervalued ASX healthcare stock
Near-term cost growth does not change our long-term view.
stocks
Sales shine but broader macro outlook darkens for this ASX share
US stores are struggling, but our investment thesis hinges on the Australian rollout.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,132.90 | 11.10 | 0.12% |
| CAC 40 | 8,245.80 | 18.07 | -0.22% |
| DAX 40 | 23,806.99 | 273.64 | -1.14% |
| Dow JONES (US) | 48,185.80 | 275.88 | 0.58% |
| FTSE 100 | 10,603.48 | 5.40 | -0.05% |
| HKSE | 26,049.45 | 297.05 | 1.15% |
| NASDAQ | 22,822.42 | 187.42 | 0.83% |
| Nikkei 225 | 56,873.57 | 978.25 | 1.75% |
| NZX 50 Index | 13,155.00 | 118.81 | -0.90% |
| S&P 500 | 6,824.66 | 41.85 | 0.62% |
| S&P/ASX 200 | 8,940.70 | 16.30 | 0.18% |
| SSE Composite Index | 4,007.25 | 41.08 | 1.04% |